Bill · S. 2294· Senate(119-S-2294)
Kay Hagan Tick Reauthorization Act
- Introduced
- 7/15/2025
- Last activity
- 7/15/2025 — Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S4370-4371)
- Sponsored by
- Susan Collins
- Cosponsors
- - 1 - 3
- Introduced
- In Committee
What this bill would do
This bill is titled the "Kay Hagan Tick Reauthorization Act." It aims to reauthorize the Kay Hagan Tick Act and serves other purposes. The legislation proposes changes to the Public Health Service Act regarding national strategies and regional centers for vector-borne diseases. It also seeks to adjust support for health departments addressing vector-borne diseases. These changes establish funding levels for the fiscal years 2026 through 2030.
Yes
Does this make health care easier to get in general?+1
The bill continues support for addressing vector-borne diseases, though at slightly reduced funding levels.
The opposite
Does this reduce what the federal government spends?-2
The bill reduces federal spending on vector-borne disease programs compared to previous authorization levels.
Does this put more money into scientific research?-1
The bill lowers the scheduled funding for research into vector-borne diseases.
Does this put more money into medical research?-1
The bill reduces the annual funding for the National Strategy and Regional Centers of Excellence in vector-borne disease.
Who it would affect, and how
Potential Positive Impacts for People
-
Funding for National Strategy and Regional Centers of Excellence in Vector-Borne Disease: The bill provides $8,000,000 for each of fiscal years 2026 through 2030 for this purpose under Section 2(a)(2).
-
Enhanced Support To Assist Health Departments in Addressing Vector-Borne Diseases: The bill provides $19,000,000 for each of fiscal years 2026 through 2030 to assist health departments under Section 2(b).
Potential Negative Impacts for People
-
Reduced Funding for National Strategy and Regional Centers of Excellence in Vector-Borne Disease: The funding level is set at $8,000,000 for each of fiscal years 2026 through 2030, which is a reduction from the $10,000,000 allocated for fiscal years 2021 through 2025 under Section 2(a)(2).
-
Reduced Funding for Enhanced Support To Assist Health Departments in Addressing Vector-Borne Diseases: The funding level is set at $19,000,000 for each of fiscal years 2026 through 2030, which is a reduction from the $20,000,000 previously allocated for fiscal years 2021 through 2025 under Section 2(b).
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Hover a score for the reason it gave.
- Economy And Finance
- Reduces Government Spending-2
- Education And Technology
- Increases Scientific Research Funding-1
- Healthcare
- Improves Healthcare Access+1Increases Research Funding-1
- 7/22/2025
- 3 Cosponsors added.
- 7/15/2025
- Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S4370-4371)
- 2 Cosponsors added.
- Introduced in Senate
One bill Congress.gov lists as related to this one — companions in the other chamber, earlier versions, and bills this one absorbed or was folded into.
Kirsten GillibrandDemocrat · New York
Josh HawleyRepublican · Missouri
Amy KlobucharDemocrat · Minnesota
Angus KingIndependent · Maine
Tina SmithDemocrat · Minnesota